SuperworthLantern Pharma EPS LTRN
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$1.62
- Latest quarter, Q2 FY26
- −$0.57
- Fiscal year 2025
- −$1.57
Lantern Pharma's earnings per share was −$1.62 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.57.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.57 | n/a |
| FY2024 | −$1.93 | n/a |
| FY2023 | −$1.48 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$1.13 | n/a |
| FY2020 | −$1.29 | n/a |
| FY2019 | −$1.23 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.57 | n/a | −$1.62 | |
| Q1 FY26 | −$0.30 | n/a | −$1.45 | |
| Q4 FY25 | −$0.36 | n/a | −$1.57 | |
| Q3 FY25 | −$0.39 | n/a | −$1.75 | |
| Q2 FY25 | −$0.40 | n/a | −$1.78 | |
| Q1 FY25 | −$0.42 | n/a | −$1.84 | |
| Q4 FY24 | −$0.54 | n/a | −$1.93 | |
| Q3 FY24 | −$0.42 | n/a | −$1.78 | |
| Q2 FY24 | −$0.46 | n/a | −$1.65 | |
| Q1 FY24 | −$0.51 | n/a | −$1.63 | |
| Q4 FY23 | −$0.39 | n/a | −$1.48 | |
| Q3 FY23 | −$0.29 | n/a | −$1.40 |
Against its peers
Companies in Drug Manufacturers - General nearest Lantern Pharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LTRNLantern Pharma | −$1.62 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lantern Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.